Puma Biotechnology Return on Equity

Puma Biotechnology (PBYI) currently reports a ROE of 19.22%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Puma Biotechnology's ROE history and peer comparisons.

Puma Biotechnology's ROE of 19.22% is lower than the Healthcare sector average of 21.67%. That is roughly 11.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Puma Biotechnology's current 19.22% should be judged against Healthcare norms (sector average: 21.67%) and against PBYI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 19.22%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Puma Biotechnology, and consider following PBYI for alerts when major investors trade the stock.

Puma Biotechnology is classified in the Healthcare sector. On ROE, it currently shows 19.22% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PBYI with unrelated industries.